about
Mutations in CIC and FUBP1 contribute to human oligodendrogliomaSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing3 Tesla intraoperative MRI for brain tumor surgery.Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionPhase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Carcinogen-specific induction of genetic instability.Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant GliomaTreatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Rapid Intraoperative Molecular Characterization of Glioma.Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsMesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes.From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.Systemic therapy of brain metastases.The role of biopsy in the management of patients with presumed diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.Glioblastoma care in the elderly.Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.Treatment of brain metastases in the modern genomic era.Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study.Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
P50
Q28244895-E438200A-82A1-41CA-8C7E-1B3A0CAA32B7Q29615604-5F803C1B-8413-49D4-BFB4-13FF41FD6AE0Q30490422-EEACAC5F-F2B4-4CE9-A539-A5626D785AF3Q30664676-992DF67D-2F5F-4CBE-A9CA-5B92FC5D0811Q30810936-850FB392-A66E-463A-BD66-9C650DE26788Q30830595-ADB79713-CD8B-45A4-B683-270DC84C9D9CQ30901996-330168B5-14BE-45AD-B1BE-012969A5FA10Q33804713-21CFD29F-6B55-4827-9A05-ADF3D4CE6FFAQ34979062-6C2EBB2E-70DA-4013-8CFB-A65C4C104E92Q35059157-B3ACEA36-5B39-4454-A3EB-DED086965C71Q35070978-1009FB4B-CF21-4420-9881-9E928E656572Q35204658-4600AA11-4DBA-4A13-BF2B-3042FCF2C393Q35895420-E4774CB0-53A2-46F1-8488-A33873FFA55BQ36385589-022F7F8A-7888-47DC-8DC6-20B41986FE38Q36558431-9CB2198F-66CA-47EE-BE6E-F5DA98593DE6Q36759382-CD6C62F8-039C-4B1E-B858-1A2849F4E053Q36887654-901375BD-4D79-4B65-A84E-27D15C876236Q36914510-379ABA55-1AB1-4983-8A25-0A6B61A8DCA6Q37028708-AF84CC7E-A28D-482F-8435-F9155ED6D94DQ37279893-639594A9-0E51-4AB6-AF0D-A7A37C6672FBQ37331928-00BAA960-B9B0-4322-B026-26F2B737A485Q37711250-48DCE457-275C-4852-AF75-DF9D0C79EAF3Q38078391-7997CA12-154F-4A47-AB5C-C0B473F1AB48Q38092769-0A4DEFEF-62AD-4407-A661-F0B84F97498BQ38168686-1EA0A69B-A27E-44D1-88B9-8C3A79E05223Q38285931-E8218192-BCF5-48B7-AF62-6704505CCC2BQ38623606-6C10D42E-BC78-4495-81E3-B335942035A6Q38623610-2CFAB01E-17DA-4A5B-AA5E-53D66B2B1285Q38627095-CE575A5A-26EE-41F8-BC3D-F5343ED4147AQ38653138-6A048C7D-A2D1-42DF-9F60-F17B45BE7A97Q38725573-A8E4A950-9D9A-4AA2-9545-92B8937406C1Q38988974-836DCA8C-D6A5-4980-B655-004587A0B9C5Q39004963-3CC0DCBD-2E69-4A48-8556-A45F7DA046C5Q39005975-C4BB331A-AAFD-4DFA-8364-DB714D56A9B1Q39024728-7218CE7D-EEE3-4886-AF9D-EDB9F1A43FADQ39154790-1E771A1B-58B8-417E-8312-9656D977A9DFQ39421788-A2C2685D-5983-44EC-8001-0CAFDC545C3FQ40396597-B2E886AE-0575-4C05-9A97-D6A5228072CCQ40711286-FE4C9407-1AA4-4235-BE99-F27B6EE06DE0Q40867510-DE83BFF1-1480-49D5-BF7E-420366D88D63
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel P Cahill
@ast
Daniel P Cahill
@en
Daniel P Cahill
@es
Daniel P Cahill
@nl
Daniel P Cahill
@sl
type
label
Daniel P Cahill
@ast
Daniel P Cahill
@en
Daniel P Cahill
@es
Daniel P Cahill
@nl
Daniel P Cahill
@sl
prefLabel
Daniel P Cahill
@ast
Daniel P Cahill
@en
Daniel P Cahill
@es
Daniel P Cahill
@nl
Daniel P Cahill
@sl
P106
P21
P31
P496
0000-0003-2552-6546